Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513608 | 1.00 | HSD11B1 (0.46) | HSD11B1HCAR1KDM4EKMT2AMEN1 | |
| SCHEMBL4500936 | 0.80 | HSD11B1 (0.41) | HSD11B1HCAR1 | |
| SCHEMBL3880991 | 0.80 | HSD11B1 (0.41) | HSD11B1HCAR1 | |
| SCHEMBL4500942 | 0.80 | HSD11B1 (0.41) | HSD11B1HCAR1 | |
| SCHEMBL4514847 | 0.77 | HSD11B1 (0.71) | HSD11B1 | |
| SCHEMBL3553955 | 0.76 | HSD11B1 (0.64) | HSD11B1KMT2AMEN1 | |
| SCHEMBL4512741 | 0.75 | HSD11B1 (0.49) | HSD11B1KMT2AMEN1 | |
| SCHEMBL4519820 | 0.74 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL2989122 | 0.74 | HSD11B1 (0.48) | HSD11B1KDM4EKMT2AMEN1CYP3A4 | |
| SCHEMBL4514552 | 0.74 | HSD11B1 (0.48) | HSD11B1KDM4EKMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HCAR1 358/4885KDM4E 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.